We are live on
!
Find out more
Alyeska Investment Group Portfolio holdings
AUM
$35.4B
1-Year Est. Return
33.54%
This Fund
S&P 500
This Quarter
Est. Return
+7.7%
1 Year Est. Return
+33.54%
3 Year Est. Return
+101.08%
5 Year Est. Return
+102.29%
10 Year Est. Return
+544.32%
AUM
$10.8B
AUM Growth
+$165M
(+1.5%)
Cap. Flow
-$365M
Cap. Flow
% of AUM
-3.38%
Top 10 Holdings %
Top 10 Hldgs %
12.81%
Holding
600
New
180
Increased
119
Reduced
126
Closed
156
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class C
GOOG
|
+$187M |
| 2 |
Apple
AAPL
|
+$156M |
| 3 |
Stryker
SYK
|
+$112M |
| 4 |
Johnson Controls International
JCI
|
+$95.3M |
| 5 |
Dell
DELL
|
+$92.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
EMC
EMC CORPORATION
EMC
|
+$126M |
| 2 |
DaVita
DVA
|
+$115M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$97.5M |
| 4 |
Johnson & Johnson
JNJ
|
+$84.2M |
| 5 |
MON
Monsanto Co
MON
|
+$81.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 16.04% |
| 2 | Healthcare | 14.31% |
| 3 | Industrials | 11.92% |
| 4 | Consumer Discretionary | 11.79% |
| 5 | Consumer Staples | 8.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
401
Pacira BioSciences
PCRX
$997M
| $1.43M | 0.01% |
+41,736
| New | +$1.64M |
|
402
AC Immune
ACIU
$240M
| $1.4M | 0.01% |
+85,000
| New | +$1.47M |
|
403
Universal Display
OLED
$4.19B
| $1.39M | 0.01% |
+25,000
| New | +$1.58M |
|
404
Fulgent Genetics
FLGT
$527M
| $1.38M | 0.01% |
+150,000
| New | +$1.38M |
|
|
IMDZ
405
DELISTED
Immune Design Corp.
IMDZ
| $1.26M | 0.01% |
+166,159
| New | +$1.21M |
|
|
ATXS
406
DELISTED
Astria Therapeutics
ATXS
| $1.22M | 0.01% |
+3,287
| New | +$866K |
|
|
BLD
407
DELISTED
TopBuild
BLD
| $1.19M | 0.01% |
+35,934
| New | +$1.27M |
|
|
WINT
408
DELISTED
Windtree Therapeutics Inc
WINT
| $1.18M | 0.01% |
461,066
-3,175
| -0.7% | -$6.91K |
|
|
KA
409
DELISTED
Kineta, Inc. Common Stock
KA
| $1.17M | 0.01% |
+536
| New | +$996K |
|
410
vTv Therapeutics
VTVT
$139M
| $1.16M | 0.01% |
4,047
+764
| +23% | +$184K |
|
|
GNCA
411
DELISTED
Genocea Biosciences, Inc.
GNCA
| $1.15M | 0.01% |
27,971
+1,113
| +4% | +$43.7K |
|
|
SCHW
412
Charles Schwab
SCHW
$187B
| $1.14M | 0.01% |
+35,942
| New | +$1.05M |
|
|
TBCH
413
Turtle Beach Corp
TBCH
$277M
| $1.11M | 0.01% |
212,500
-70,256
| -25% | -$296K |
|
|
APTI
414
DELISTED
Apptio, Inc. Class A Common Stock
APTI
| $1.08M | 0.01% |
+50,000
| New | +$1.1M |
|
|
MRC
415
DELISTED
MRC Global
MRC
| $1.05M | 0.01% |
+63,724
| New | +$913K |
|
|
WBT
416
DELISTED
Welbilt, Inc.
WBT
| $1.01M | 0.01% |
+62,167
| New | +$1.06M |
|
|
ARGS
417
CALL
DELISTED
Argos Therapeutics, Inc.
ARGS
| $994K | 0.01% |
+10,000
| New | +$1.04M |
|
|
MNK
418
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $986K | 0.01% |
+14,136
| New | +$1.02M |
|
|
NVRO
419
DELISTED
NEVRO CORP.
NVRO
| $919K | 0.01% |
8,808
-32,559
| -79% | -$2.94M |
|
|
AGN
420
DELISTED
Allergan plc
AGN
| $745K | 0.01% |
+3,233
| New | +$790K |
|
|
XTLY
421
DELISTED
Xactly Corporation
XTLY
| $736K | 0.01% |
50,000
-300,000
| -86% | -$4.02M |
|
|
BLRX
422
BioLineRX
BLRX
$11.8M
| $733K | 0.01% |
1,062
+42
| +4% | +$22.4K |
|
423
Trade Desk
TTD
$6.49B
| $730K | 0.01% |
+250,000
| New | +$738K |
|
424
Spyre Therapeutics
SYRE
$9.25B
| $703K | 0.01% |
4,386
+386
| +10% | +$53.7K |
|
|
DERM
425
DELISTED
Dermira, Inc.
DERM
| $653K | 0.01% |
19,299
-62,693
| -76% | -$2.02M |
|
Similar funds
SAM
VIA
Alyeska Investment Group's Q3 2016 Portfolio in Review
As of Q3 2016, Alyeska Investment Group held 600 positions worth $10.8B, up 1.5% from $10.6B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Alyeska Investment Group withdrew a net $365M in Q3 2016, closing 156 positions and reducing 126 holdings. Its most notable exit was EMC CORPORATION, an estimated $126M position sold in full.
By sector, the portfolio is most concentrated in Technology at 16% of assets, up from 15% a quarter earlier, followed by Healthcare and Industrials.
Against the trend, Alyeska Investment Group opened a new position in Alphabet (Google) Class C worth $192M.
- Alyeska Investment Group's largest Q3 2016 buy was Alphabet (Google) Class C: 4,931,700 shares worth $192M.
- Alyeska Investment Group added most to Apple in Q3 2016, an estimated $156M increase.
- Alyeska Investment Group's biggest Q3 2016 reduction was Alphabet (Google) Class A, cutting an estimated $97.5M.
- Alyeska Investment Group fully exited EMC CORPORATION in Q3 2016, selling an estimated $126M.
- Alyeska Investment Group's ten largest holdings make up 13% of its $10.8B portfolio in Q3 2016.
- Alyeska Investment Group opened 180 new positions and closed 156 in Q3 2016.
- Alyeska Investment Group's portfolio value rose 1.5% quarter-over-quarter to $10.8B.
Based on Alyeska Investment Group's 13F filing for Q3 2016, filed 14 Nov 2016.